Article Sidebar
Published:
Mar 12, 2019Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Therapeutic efficacy of combined administration of thymosin and oxaliplatin in elderly gastric ulcer patients and its effect on cellular immunity and matrix metalloproteinase
Abstract
Purpose: To investigate the clinical efficacy of thymosin combined with oxaliplatin and tiggio in aged gastric cancer (GC) sufferers, as well as their impact on cellular immunity and matrix metalloproteinase.
Methods: Elderly GC sufferers (n = 82) were divided into study and control groups by random allocation (41 patients/group). Control group was treated with oxaliplatin combined with tiggio, while the study group was treated with thymopeptide injection, in addition to oxaliplatin combined with tiggio. Each treatment course lasted 21 days, and the study involved three courses. Clinical effectiveness and toxicity in the two groups were determined and compared before and after treatment.
Results: Total effectiveness in the study group (73.16 %) and disease remission (95.11 %) were superior to the corresponding values for control patients given oxaliplatin and tiggio (48.78 and 85.37 %, respectively, p ˂ 0.05). There were markedly lower incidences of nausea, vomiting and leukopenia in the study group than in control (p ˂ 0.05).
Conclusion: The use of thymosin-oxaliplatin-tigeo triple therapy for aged GC sufferers has a definite clinical benefits and low toxic side effects.
Keywords: Thymosin, Asha Leigh Per, Teggio, Gastric cancer, Cellular immunity, Matrix metalloproteinase
